Segment Information - Schedule of Company Revenue and Adjusted EBITDA by Segment (Details) - USD ($) $ in Thousands		3 Months Ended							9 Months Ended
		Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021		Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021
Segment Adjusted EBITDA
Total Adjusted EBITDA		$ (43,272)			$ (64,012)				$ (122,642)	$ (120,970)
Net income (loss)		(91,961)	$ (66,065)	$ (89,532)	(89,396)		$ (16,524)	$ (42,026)	(247,558)	(147,946)
Adjustments
Interest (income) expense, net		(3,671)			(76)				(5,307)	(213)
Other income (expense), net		855			22				(267)	39
Change in fair value of warrant liabilities		0			(3,695)				0	(32,989)
Income tax benefit		(613)			(3,512)				(2,139)	(3,512)
Depreciation and Amortization		5,257			4,681				15,512	14,188
Amortization Of Acquired Intangible Assets		4,265			2,898				12,847	2,898
Impairment of acquired intangible assets		9,968							9,968
Stock-based compensation expense		34,338			17,409				93,768	37,473
Acquisition-related costs					7,701	[1]				9,170	[1]
Total Adjusted EBITDA		(43,272)			(64,012)				(122,642)	(120,970)
Consumer And Research Services [Member]
Segment Revenue
Total Revenue		66,940			56,891				207,112	171,334
Segment Adjusted EBITDA
Total Adjusted EBITDA		(8,313)			(31,967)				(22,986)	(33,232)
Therapeutics
Segment Revenue
Total Revenue	[2]	66,940			56,891				207,112	171,334
Segment Adjusted EBITDA
Total Adjusted EBITDA		(21,471)			(19,916)				(58,599)	(57,046)
Unallocated Corporate [Member]
Segment Adjusted EBITDA
Total Adjusted EBITDA		$ (13,488)			$ (12,129)				$ (41,057)	$ (30,692)

[1] For the three and nine months ended December 31, 2021, acquisition-related costs primarily consisted of advisory, legal and consulting fees.

[2] There was no Therapeutics revenue for the three and nine months ended December 31, 2022 and 2021.